French biotech based near Montpellier, specialised in long-acting injectable formulations through its BEPO® platform. Its thesis rests on a royalty model from partnerships with major pharma companies.

Swiss/Icelandic ophthalmology biotech listed on Nasdaq. Oculis is developing a focused pipeline of topical and neuroprotective candidates for major ophthalmic markets: diabetic macular oedema, dry eye disease, retinal neuroprotection.